GB9513371D0
(en)
*
|
1995-06-30 |
1995-09-06 |
Biocine Spa |
Immunogenic detoxified mutant toxins
|
ATE275970T1
(de)
|
1993-10-05 |
2004-10-15 |
Celltech Pharmaceuticals Ltd |
Impfstoffzusammensetzungen
|
GB9326174D0
(en)
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
US5981730A
(en)
*
|
1994-04-13 |
1999-11-09 |
The General Hospital Corporation |
RPS gene family, primers, probes, and detection methods
|
US6436407B1
(en)
|
1994-08-26 |
2002-08-20 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic adjuvant
|
US6019982A
(en)
*
|
1994-08-26 |
2000-02-01 |
The Administrators Of The Tulane Educational Fund |
Mutant enterotoxin effective as a non-toxic oral adjuvant
|
GB9603314D0
(en)
*
|
1996-02-16 |
1996-04-17 |
Biocine Spa |
Immunogenic detoxified mutant toxins
|
GB9622660D0
(en)
*
|
1996-10-31 |
1997-01-08 |
Biocine Spa |
Immunogenic detoxified mutant toxin
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
WO1998023763A1
(en)
*
|
1996-11-29 |
1998-06-04 |
The General Hospital Corporation |
Heterologous antigens in live cell v. cholerae strains
|
AU6044598A
(en)
*
|
1997-01-29 |
1998-08-18 |
The Administrators Of The Tulane Eductional Fund |
Mutant enterotoxin effective as a non-toxic adjuvant for hiv
|
EP1486215A3
(en)
*
|
1997-03-21 |
2006-04-12 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
US6818222B1
(en)
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
EP0887403A3
(en)
*
|
1997-06-27 |
2000-12-06 |
Chiron S.P.A. |
Attenuated Vibrio cholerae strains
|
WO1999010372A1
(en)
|
1997-08-27 |
1999-03-04 |
Chiron Corporation |
Molecular mimetics of meningococcal b epitopes
|
AU3089599A
(en)
*
|
1998-03-18 |
1999-10-11 |
Smithkline Beecham Corporation |
Production of purified mutant enterotoxin for use as an adjuvant
|
US6033673A
(en)
*
|
1998-03-18 |
2000-03-07 |
The Administrators Of Tulane Educational Fund |
Double mutant enterotoxin for use as an adjuvant
|
US6576244B1
(en)
|
1998-06-19 |
2003-06-10 |
Acambis, Inc. |
LT and CT in parenteral immunization methods against helicobacter infection
|
DE19851282A1
(de)
*
|
1998-11-06 |
2000-05-11 |
Schweiz Serum & Impfinst |
Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten
|
EP1175144A4
(en)
*
|
1998-12-22 |
2002-10-30 |
Thompson Boyce Plant Res |
ORAL ADMINISTRATION IMMUNOGENIC BACTERIAL ENTEROTOXINS EXPRESSED IN TRANSGENIC PLANTS
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
WO2000039302A2
(en)
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
CA2689696C
(en)
|
1999-02-26 |
2013-08-06 |
Novartis Vaccines And Diagnostics, Inc. |
Microemulsions with adsorbed macromolecules and microparticles
|
JP2002537355A
(ja)
|
1999-02-26 |
2002-11-05 |
カイロン コーポレイション |
抗原の粘膜送達のための生体接着剤およびアジュバントの使用
|
US7115730B1
(en)
|
1999-04-27 |
2006-10-03 |
Chiron Srl |
Immunogenic detoxified mutant E. coli LT-A-toxin
|
GB9919468D0
(en)
|
1999-08-17 |
1999-10-20 |
Smithkline Beecham Biolog |
Vaccine
|
WO2001019998A1
(en)
*
|
1999-09-15 |
2001-03-22 |
Mogam Biotechnology Research Institute |
Novel detoxified mutants of escherichia coli heat-labile enterotoxin
|
US7186560B2
(en)
*
|
1999-09-21 |
2007-03-06 |
Rutgers, The State University Of New Jersey |
High level expression of immunogenic proteins in the plastids of higher plants
|
CA2385484A1
(en)
*
|
1999-09-21 |
2001-03-29 |
Rutgers, The State University Of New Jersey |
Site-specific recombination system to manipulate the plastid genome of higher plants
|
GB9923060D0
(en)
|
1999-09-29 |
1999-12-01 |
Chiron Spa |
Vaccine
|
US7384640B1
(en)
|
1999-09-30 |
2008-06-10 |
Wyeth Holdings Corporation |
Mutant cholera holotoxin as an adjuvant
|
JP5072159B2
(ja)
|
1999-10-26 |
2012-11-14 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
粘膜アジュバントとしての植物レクチン
|
WO2001070257A1
(en)
*
|
2000-03-17 |
2001-09-27 |
Uab Research Foundation |
Chimeric nontoxic mutants of enterotoxins as mucosal adjuvants for cell-mediated or humoral immunity
|
WO2001089456A2
(en)
*
|
2000-05-19 |
2001-11-29 |
The Administrators Of The Tulane Educational Fund |
Hybrid lt-a/ct-b holotoxin for use as an adjuvant
|
WO2002046477A2
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
EP1363663B1
(en)
|
2001-01-12 |
2011-03-02 |
Novartis Vaccines and Diagnostics, Inc. |
Nucleic acid mucosal immunization
|
EP2316482A1
(en)
|
2001-03-19 |
2011-05-04 |
Intercell USA, Inc. |
Transcutaneous immunostimulation
|
US7534936B2
(en)
*
|
2001-03-29 |
2009-05-19 |
Rutgers, The State University Of New Jersey |
Transgenic plants having transformed plastid genomes and progeny thereof
|
DK2292802T3
(en)
|
2001-05-22 |
2015-03-09 |
Us Gov Health & Human Serv |
Development of mutations useful for attenuation of dengue viruses and chimeric dengue viruses
|
IL159209A0
(en)
|
2001-06-07 |
2004-06-01 |
Wyeth Corp |
Mutant forms of cholera holotoxin as an adjuvant
|
AU2002346249B2
(en)
*
|
2001-06-07 |
2007-03-15 |
The Regents Of The University Of Colorado |
Mutant Forms of Cholera Holotoxin as an Adjuvant
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
WO2003004657A1
(en)
|
2001-07-05 |
2003-01-16 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
|
EP2412242A3
(en)
|
2001-07-05 |
2012-06-13 |
Novartis Vaccines and Diagnostics, Inc. |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
ES2615362T3
(es)
|
2001-07-27 |
2017-06-06 |
Glaxosmithkline Biologicals Sa |
Adhesinas de meningococos
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
EP2572707A3
(en)
|
2002-02-20 |
2013-11-06 |
Novartis Vaccines and Diagnostics, Inc. |
Microparticles with adsorbed polypeptide-containing molecules
|
JP2005532789A
(ja)
|
2002-03-15 |
2005-11-04 |
ワイス・ホールデイングス・コーポレーシヨン |
減少した酵素活性を有する型別不能なインフルエンザ菌(Haemophilusinfluenza)のP4タンパク質の変異体
|
EP1532161B1
(en)
|
2002-06-13 |
2012-02-15 |
Novartis Vaccines and Diagnostics, Inc. |
Vectors for expression of hml-2 polypeptides
|
JP2005539039A
(ja)
*
|
2002-08-27 |
2005-12-22 |
ダウ アグロサイエンシィズ エルエルシー |
鳥類及び家禽類におけるアジュバントとしてのエシェリシア・コリ熱不安定性毒素の使用
|
US20080159957A1
(en)
|
2002-10-01 |
2008-07-03 |
W Michael Kavanaugh |
Anti-Cancer and Anti-Infectious Disease Compositions and Methods for Using Same
|
DK2395073T3
(en)
|
2002-11-01 |
2017-10-23 |
Glaxosmithkline Biologicals Sa |
Process for drying.
|
WO2004043286A2
(en)
*
|
2002-11-14 |
2004-05-27 |
Pfizer Products Inc. |
Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
|
WO2004060396A2
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenic compositions containing phospholpid
|
US6743002B1
(en)
*
|
2003-02-03 |
2004-06-01 |
Eaton Corporation |
Rotary fluid pressure device and improved integral brake assembly
|
US20040171565A1
(en)
*
|
2003-02-14 |
2004-09-02 |
David Hone |
DNA vaccines that expresses mutant ADP-ribosyltransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity
|
EP1606386A4
(en)
*
|
2003-03-03 |
2007-07-18 |
Univ Rutgers |
REMOVAL OF PLASTIC SEQUENCES THROUGH TRANSIENT EXPRESSED LOCATION-SPECIFIC RECOMBINATION
|
WO2004083251A2
(en)
*
|
2003-03-17 |
2004-09-30 |
Wyeth Holdings Corporation |
Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
|
GB0308198D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
WO2005020964A1
(en)
|
2003-06-02 |
2005-03-10 |
Chiron Corporation |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
GB0313242D0
(en)
*
|
2003-06-09 |
2003-07-16 |
Imp College Innovations Ltd |
Pulmonary immunopathology
|
PL1660123T3
(pl)
|
2003-09-02 |
2013-08-30 |
Glaxosmithkline Biologicals Sa |
Szczepionka rotawirusowa
|
US20100015211A1
(en)
|
2004-11-01 |
2010-01-21 |
Barnett Susan W |
Combination Approaches For Generating Immune Responses
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
KR20150061019A
(ko)
|
2005-04-08 |
2015-06-03 |
와이어쓰 엘엘씨 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
JP2009511636A
(ja)
|
2005-10-18 |
2009-03-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
|
US8143474B2
(en)
*
|
2006-04-18 |
2012-03-27 |
Rutgers, The State University Of New Jersey |
Compositions and methods for increasing transgene expression in the plastids of higher plants
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
WO2008094188A2
(en)
|
2006-07-17 |
2008-08-07 |
Anza Therapeutics, Inc. |
Methods and compositions using listeria for enhancing immunogenicity by prime boost
|
JP2010530895A
(ja)
*
|
2007-06-21 |
2010-09-16 |
アンジェリカ セラピューティックス,インク. |
修飾毒素
|
EP2244695A1
(en)
|
2007-12-07 |
2010-11-03 |
Novartis AG |
Compositions for inducing immune responses
|
WO2009110944A1
(en)
*
|
2008-02-29 |
2009-09-11 |
Angelica Therapeutics, Inc. |
Modified toxins
|
US9415006B2
(en)
|
2008-05-23 |
2016-08-16 |
The Regents Of The University Of Michigan |
Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
|
WO2009155484A2
(en)
|
2008-06-20 |
2009-12-23 |
Wyeth |
Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
|
US20100092526A1
(en)
|
2008-09-26 |
2010-04-15 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
US9023363B2
(en)
*
|
2008-10-21 |
2015-05-05 |
International Vaccine Institute |
A1 moiety of cholera toxin A subunit as an adjuvant for mucosal and systemic vaccines
|
BRPI1005670A8
(pt)
|
2009-01-05 |
2017-12-26 |
Epitogenesis Inc |
composições adjuvantes e processos de uso.
|
EP2405758B1
(en)
|
2009-03-09 |
2016-04-27 |
Molecular Express, Inc. |
Methods and compositions for liposomal formulation of antigens and uses thereof
|
ES2566646T3
(es)
|
2009-06-16 |
2016-04-14 |
The Regents Of The University Of Michigan |
Vacunas en nanoemulsión
|
SG10201406432RA
(en)
|
2009-06-22 |
2014-11-27 |
Wyeth Llc |
Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
|
BRPI1015567A2
(pt)
|
2009-06-22 |
2021-08-31 |
Wyeth Llc |
Composições imunogênicas de antígenos de staphylococcus aureus
|
AR077636A1
(es)
|
2009-07-08 |
2011-09-14 |
Abbott Biologicals Bv |
Vacuna viral y uso de la misma
|
US8241608B2
(en)
|
2010-03-23 |
2012-08-14 |
Development Center For Biotechnology |
Treating allergy with detoxified E. coli heat-labile enterotoxin
|
ES2613630T3
(es)
|
2010-05-23 |
2017-05-25 |
Aduro Biotech, Inc. |
Métodos y composiciones que utilizan Listeria para un tratamiento auxiliar del cáncer
|
HUE048398T2
(hu)
|
2010-06-04 |
2020-07-28 |
Wyeth Llc |
Vakcinakészítmények
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
HUE052850T2
(hu)
|
2010-08-23 |
2021-05-28 |
Wyeth Llc |
Neisseria meningitidis RLP2086 antigéneket tartalmazó stabil készítmények
|
NZ607224A
(en)
|
2010-09-10 |
2014-11-28 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
DK2654784T3
(en)
|
2010-12-22 |
2017-02-13 |
Wyeth Llc |
STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES
|
US20140287022A1
(en)
|
2011-04-26 |
2014-09-25 |
Molecular Express, Inc. |
Liposomal formulations
|
CN103717235A
(zh)
|
2011-06-24 |
2014-04-09 |
埃皮托吉尼西斯有限公司 |
作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
|
MX2014005548A
(es)
|
2011-11-14 |
2014-08-21 |
Novartis Ag |
Complejos inmunogenicos de carbomeros polianionicos y polipeptidos env y metodos de manufactura y usos de los mismos.
|
KR101763625B1
(ko)
|
2012-03-09 |
2017-08-01 |
화이자 인코포레이티드 |
수막염균 조성물 및 이의 사용 방법
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
EP3608401A1
(en)
|
2012-07-05 |
2020-02-12 |
Ohio State Innovation Foundation |
Compositions and methods related to viral vaccines
|
WO2014044690A1
(en)
|
2012-09-18 |
2014-03-27 |
Valneva Austria Gmbh |
Improved vaccines
|
DK2912186T3
(da)
|
2012-10-24 |
2021-02-22 |
Platelet Targeted Therapeutics Llc |
Behandling rettet mod blodplader
|
CA2943263C
(en)
|
2012-12-20 |
2018-12-04 |
Pfizer Inc. |
Glycoconjugation process
|
CN105188747A
(zh)
|
2013-02-01 |
2015-12-23 |
葛兰素史密斯克莱生物公司 |
包含toll样受体激动剂的免疫组合物的皮内递送
|
ES2685894T3
(es)
|
2013-03-08 |
2018-10-15 |
Pfizer Inc. |
Polipéptidos de fusión inmunogénicos
|
CA2902905A1
(en)
|
2013-03-15 |
2014-09-25 |
Claude Geoffrey Davis |
Modified toxins
|
RU2662968C2
(ru)
|
2013-09-08 |
2018-07-31 |
Пфайзер Инк. |
Иммуногенная композиция против neisseria meningitidis (варианты)
|
EP3063171B1
(en)
|
2013-11-01 |
2019-07-24 |
University Of Oslo |
Albumin variants and uses thereof
|
US9993541B2
(en)
|
2013-11-13 |
2018-06-12 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
WO2015071763A2
(en)
|
2013-11-15 |
2015-05-21 |
Oslo Universitetssykehus Hf |
Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
WO2016130569A1
(en)
|
2015-02-09 |
2016-08-18 |
Mj Biologics, Inc. |
A composition comprising pedv antigens and methods for making and using the composition
|
WO2015138455A1
(en)
|
2014-03-11 |
2015-09-17 |
Regents Of The University Of Minnesota |
Porcine epidemic diarrhea virus vaccines and methods of use thereof
|
US11083788B2
(en)
|
2014-10-10 |
2021-08-10 |
The Regents Of The University Of Michigan |
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
|
EP3270959A1
(en)
|
2015-02-19 |
2018-01-24 |
Pfizer Inc |
Neisseria meningitidis compositions and methods thereof
|
WO2016141320A2
(en)
|
2015-03-05 |
2016-09-09 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
WO2016179034A2
(en)
|
2015-05-01 |
2016-11-10 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
|
PE20180172A1
(es)
|
2015-05-04 |
2018-01-22 |
Pfizer |
Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
|
CN108348593B
(zh)
|
2015-08-31 |
2022-08-16 |
泰克诺瓦克斯股份有限公司 |
基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
|
WO2017062246A1
(en)
|
2015-10-05 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human rota virus g9p[6] strain and use as a vaccine
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
WO2017158426A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Engineered immunoglobulins with altered fcrn binding
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
WO2017210215A1
(en)
|
2016-05-31 |
2017-12-07 |
The Government Of The United States Of America As Represented By The Secretary Of The Army |
Zika virus vaccine and methods of production
|
EP3471761A2
(en)
|
2016-06-21 |
2019-04-24 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
SG11201906519RA
(en)
|
2017-01-31 |
2019-08-27 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
WO2018183666A1
(en)
|
2017-03-31 |
2018-10-04 |
Boston Medical Center Corporation |
Methods and compositions using highly converved pneumococcal surface proteins
|
JP2020533338A
(ja)
|
2017-09-07 |
2020-11-19 |
ユニバーシティ オブ オスロUniversity of Oslo |
ワクチン分子
|
WO2019048936A1
(en)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
VACCINE MOLECULES
|
AU2021211012A1
(en)
|
2020-01-24 |
2022-08-25 |
Aim Immunotech Inc. |
Methods, compositions, and vaccines for treating a virus infection
|
US20230146256A1
(en)
|
2020-04-17 |
2023-05-11 |
Regents Of The University Of Minnesota |
SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
|
US20230321212A1
(en)
|
2020-08-26 |
2023-10-12 |
Pfizer Inc. |
Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
|
EP4313132A1
(en)
|
2021-03-31 |
2024-02-07 |
Vib Vzw |
Vaccine compositions for trypanosomatids
|
CN113788893B
(zh)
*
|
2021-08-11 |
2022-08-09 |
中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) |
一种快速富集霍乱弧菌的偶联特异性单克隆抗体的免疫磁珠及其制备方法
|